On July 21, 2025, SAB Biotherapeutics, Inc. entered into a securities purchase agreement to issue and sell 1,000,000 shares of Series B Preferred Stock and warrants, aiming to raise approximately $175 million for its Phase 2b SAFEGUARD study and general purposes. The Preferred Stock will convert into common stock at $1.75 per share, subject to stockholder approval.